Sangamo Therapeutics, Inc. (NASDAQ: SGMO) and Pfizer, Inc. (NYSE: PFE) announced updated results from the Phase 1/2 Alta study evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

GSK, Pfizer (PFE) & Shionogi Ltd. Joint-Owned Company, ViiV Healthcare, Reports Phase III TANGO Study Meets Primary EndpointJuly 10, 2019 6:09 AM Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII LevelsJuly 5, 2019 11:15 PM